Researchers identified specific receptors for acetylcholine that reroute information flow through memory circuits in the hippocampus. The findings could have implications for the development of drugs to help enhance or protect memory from diseases associated with cognitive decline.
Allopregnanolone, a neuroactive steroid used in the treatment of postpartum depression, alters neural communication in the basolateral amygdala, an area of the brain associated with emotion and mood regulation. The drug may alter the network associated with chronic stress, which may explain its persistent antidepressant effect.
Long-term circadian rhythm disruptions induce Alzheimer's disease-like pathology in rats, which can be reversed by administering fluoxetine. Additionally, elevated levels of amyloid beta and circadian rhythm disruptions can trigger each other, leading to the cascade of neurological symptoms of dementia.
Dipeptidyl peptidase-4 inhibitors, a class of drug that reduces blood sugar in type 2 diabetes, were associated with less amyloid accumulation in the brain and slower cognitive decline in patients.
Researchers have developed a new brain organoid model to study the mechanistic causes of Alzheimer's disease and test dementia drugs currently in development.
Combining two natural products that modulate the epigenome, researchers believe they have identified a feasible approach to reversing symptoms of PTSD in animal models that could be effective in humans.
A new dual-drug therapy for alcohol use disorder appears to be effective and has fewer side effects or complications compared to other medications used to treat AUD.
Riluzole, a drug commonly prescribed to slow the progression of ALS, appears to slow brain metabolic decline and improve cognitive performance in those with mild Alzheimer's disease.
Alterations in long-term social behavior and gene expression were observed in the offspring of mice exposed to pain-killing opioids during pregnancy.